EDAP TMS SA to Announce Second Quarter 2022 Financial Results on August 24th, 2022

Rhea-AI Summary

EDAP TMS SA (Nasdaq: EDAP) will announce its Q2 2022 financial results on August 24, 2022, after market close. A conference call and webcast will follow on August 25 at 8:30 am EDT, featuring key executives including Marc Oczachowski, Ryan Rhodes, and François Dietsch. EDAP TMS is recognized for its advancements in robotic energy-based therapies and ultrasound technology for medical devices, particularly in prostate cancer treatment.

Positive

• Scheduled release of Q2 2022 financial results may indicate readiness for transparency and investor engagement.
• Company's leadership in robotic energy-based therapies could attract investors interested in innovative medical solutions.

Negative

• None.

Company to host conference call and webcast on Thursday, August 25^th at 8:30 am EDT

LYON, France, August 3, 2022 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30^th after the markets close on Wednesday, August 24^th, 2022.

An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Thursday, August 25^th, 2022. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast
Thursday, August 25^th@ 8:30am Eastern Time
Domestic:        877-451-6152
International:        201-389-0879
Passcode:        13731177
Webcast:        https://viavid.webcasts.com/starthere.jsp?ei=1558239&tp_key=295933838c

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

Company contact:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
John Fraunces
LifeSci Advisors, LLC
212-915-2568
jfraunces@lifesciadvisors.com

 

FAQ

When will EDAP TMS release its Q2 2022 financial results?

EDAP TMS will release its Q2 2022 financial results on August 24, 2022.

What time is the EDAP TMS conference call?

The EDAP TMS conference call will be held at 8:30 am EDT on August 25, 2022.

Who will lead the conference call for EDAP TMS?

The conference call will be led by Marc Oczachowski, Ryan Rhodes, and François Dietsch.

What is EDAP TMS known for?

EDAP TMS is known for its leadership in robotic energy-based therapies and minimally invasive medical devices using ultrasound technology.